Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company based in Chatham, has purchased a 44-acre site in Montana to build a vaccine development and commercial-scale manufacturing facility, it announced Wednesday.
The project comes on the heels of Tonix’s September purchase of a 40,000-square-foot facility in Massachusetts to house its Advanced Development Center for development and manufacture of vaccines.
Both sites are expected to support development and production of Tonix’s vaccine candidates, including potential products for horsepox, COVID-19, smallpox, monkeypox and more.
“The COVID-19 pandemic exposed weaknesses in the U.S. domestic vaccine development and manufacturing capabilities,” Dr. Seth Lederman, CEO and president of Tonix, said in a prepared statement. “Tonix seeks to be a leader in the redomestication of American vaccine development and production.”
